Control | Mobile telephone | p-value | |
Subjects | 46 | 43 | |
Age yrs | 54.0±2.4 | 50.4±1.9 | 0.247 |
Males | 22 (47.8) | 22 (51.2) | 0.756 |
BMI kg·m−2 | 24.3±0.5 | 24.0±0.5 | 0.672 |
SF-12® PCS | 43.2±1.4 | 41.6±1.5 | 0.460 |
SF-12® MCS | 48.6±1.2 | 48.6±1.1 | 0.886 |
FVC L | 2.01±0.11 | 2.18±0.11 | 0.138 |
FEV1 L | 1.57±0.09 | 1.40±0.09 | 0.083 |
FEV1 % pred | 58.2±3.1 | 57.9±3.0 | 0.825 |
FEV1/FVC % | 68.4±1.8 | 70.5±1.7 | 0.297 |
PEFR L·min−1 | 350.1±7.8 | 352.2±10.3 | 0.997 |
Inhaled corticosteroids# μg | 619.6±33.6 | 604.7±41.0 | 0.546 |
Systemic corticosteroids¶ mg | 1.3±0.4 | 1.2±0.4 | 0.886 |
Systemic corticosteroids¶ | 9 (19.6) | 8 (18.6) | 0.908 |
Antileukotrienes+ | 14 (30.4) | 19 (44.2) | 0.180 |
Data are presented as n, mean±sem or n (%), unless otherwise stated. BMI: body mass index; SF: Short Form; PCS: physical component score; MCS: mental component score; FVC: forced vital capacity; FEV1: forced expiratory volume in 1 s; % pred: % predicted; PEFR: peak expiratory flow rate. #: fluticasone propionate or equivalent. ¶: prednisolone. +: montelukast.